

Approved for use through 07/31/2006 OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/517,869
		Filing Date	October 12, 2005
		First Named Inventor	Anders Lehmann
		Art Unit	1614
		Examiner Name	Spivack, Phyllis G.
Sheet	1	of	1
		Attorney Docket Number	1103326-0946

U.S. PATENT DOCUMENTS

Examiner Initials ⁵	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages/Figures Appear
		Number-Kind Code ³ (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials ⁵	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ³ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ⁵	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
/P.S./		Patentee AstraZeneca's response, dated 25 June 2009, to the Opposition against EP 1 513 525 B1 filed by Addex Pharma S.A. and separately by Novartis AG.	
/P.S./		The EPO's preliminary and non-binding opinion dated 19 October 2009 with regard to the Opposition against EP 1 513 525 B1.	
/P.S./		Supplemental submission, dated 28 July 2010, by the opponent Novartis AG in its Opposition against EP 1 513 525 B1.	
/P.S./		Trilateral Project B3b: Mutual understanding in search and examination: Report on comparative study on biotechnology patent practices: Theme – comparative study on “reach-through claims”, EPO, JPO, USPTO, November 5-9, 2001.	
Examiner Signature	/Phyllis Spivack/	Date Considered	09/26/2010

¹EXAMINER: Initial if reference considered, whether or not citation is in accordance with MPEP § 609. Draw how thorough citation if not in accordance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinda Codes of USPTO Patent Documents in www.uspto.gov or MPEP § 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard 57.3). ⁵For Japanese patent documents, cite in addition, office of publication (if any). ⁶If the document is not available in English, the applicant must provide the actual number of the patent document. ⁷Relevant documents by the applicant are not required to be submitted. ⁸Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.57 and 1.59. The information is required to obtain or retain a benefit by the public which is in this (and by the USPTO to present) in publication. Confidentiality is governed by 35 USC 1.57 and 1.59. ⁹This collection is intended to make it easier to complete the form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.